Now Available for Public Comment: Notice of Proposed Rulemaking (NPRM) for FDAAA 801 and NIH Draft Reporting Policy for NIH-Funded Trials

National Survey on Infiltrative Breast Cancer (CSI)

This study has been completed.
Information provided by:
AstraZeneca Identifier:
First received: June 10, 2008
Last updated: December 9, 2010
Last verified: December 2010

June 10, 2008
December 9, 2010
June 2007
July 2008   (final data collection date for primary outcome measure)
Radiological, Clinical and Histological characteristics [ Time Frame: Once ]
Same as current
Complete list of historical versions of study NCT00696527 on Archive Site
Treatments: Surgery, radiotherapy, chemotherapy, hormonotherapy. [ Time Frame: Once ]
Same as current
Not Provided
Not Provided
National Survey on Infiltrative Breast Cancer
National Prospective Survey on Women With a Diagnosis of Infiltrative Breast Cancer

The purpose of this observational study is to describe radiological, clinical and histological characteristics of women with infiltrative breast cancer.

Not Provided
Observational Model: Cohort
Time Perspective: Prospective
Not Provided
Not Provided
Probability Sample

First ten consecutive women with infiltrative breast cancer seen by oncologists, and fulfilling eligibility criteria.

Infiltrative Breast Cancer
Not Provided
Not Provided

*   Includes publications given by the data provider as well as publications identified by Identifier (NCT Number) in Medline.
July 2008
July 2008   (final data collection date for primary outcome measure)

Inclusion Criteria:

  • Women> or = 18 years old
  • Women with newly diagnosis of infiltrative breast cancer
  • Agree to take part in this study

Exclusion Criteria:

  • Women with other malignant tumor (except in situ cervical carcinoma or treated basal cell carcinoma)
  • Women with in situ ductal carcinoma or in situ lobular carcinoma
18 Years and older
Contact information is only displayed when the study is recruiting subjects
Alain Castaigne, Medical Director, AstraZeneca Pharmaceuticals
Not Provided
Study Director: Alain Castaigne, Medical Director AstraZeneca
December 2010

ICMJE     Data element required by the International Committee of Medical Journal Editors and the World Health Organization ICTRP